Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
Oberlin O, Fawaz O, Rey A, Niaudet P, Ridola V, Orbach D, Bergeron C, Defachelles AS, Gentet JC, Schmitt C, Rubie H, Munzer M, Plantaz D, Deville A, Minard V, Corradini N, Leverger G, de Vathaire F. Oberlin O, et al. Among authors: rey a. J Clin Oncol. 2009 Nov 10;27(32):5350-5. doi: 10.1200/JCO.2008.17.5257. Epub 2009 Oct 13. J Clin Oncol. 2009. PMID: 19826134
Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant.
Oberlin O, Rey A, Desfachelles AS, Philip T, Plantaz D, Schmitt C, Plouvier E, Lejars O, Rubie H, Terrier P, Michon J; Société Française des Cancers de l'Enfant. Oberlin O, et al. Among authors: rey a. J Clin Oncol. 2006 Aug 20;24(24):3997-4002. doi: 10.1200/JCO.2006.05.7059. J Clin Oncol. 2006. PMID: 16921053 Clinical Trial.
Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study.
Oberlin O, Rey A, Sanchez de Toledo J, Martelli H, Jenney ME, Scopinaro M, Bergeron C, Merks JH, Bouvet N, Ellershaw C, Kelsey A, Spooner D, Stevens MC. Oberlin O, et al. Among authors: rey a. J Clin Oncol. 2012 Jul 10;30(20):2457-65. doi: 10.1200/JCO.2011.40.3287. Epub 2012 Jun 4. J Clin Oncol. 2012. PMID: 22665534 Clinical Trial.
Infantile fibrosarcoma: management based on the European experience.
Orbach D, Rey A, Cecchetto G, Oberlin O, Casanova M, Thebaud E, Scopinaro M, Bisogno G, Carli M, Ferrari A. Orbach D, et al. Among authors: rey a. J Clin Oncol. 2010 Jan 10;28(2):318-23. doi: 10.1200/JCO.2009.21.9972. Epub 2009 Nov 16. J Clin Oncol. 2010. PMID: 19917847
Risk adapted chemotherapy for localised Ewing's sarcoma of bone: the French EW93 study.
Gaspar N, Rey A, Bérard PM, Michon J, Gentet JC, Tabone MD, Roché H, Defachelles AS, Lejars O, Plouvier E, Schmitt C, Bui B, Boutard P, Taque S, Munzer M, Vannier JP, Plantaz D, Entz-Werle N, Oberlin O. Gaspar N, et al. Among authors: rey a. Eur J Cancer. 2012 Jun;48(9):1376-85. doi: 10.1016/j.ejca.2012.03.017. Epub 2012 Apr 18. Eur J Cancer. 2012. PMID: 22516209 Clinical Trial.
Phase II study of cisplatin and oral VP16 in patients with refractory or relapsed Ewing sarcoma.
Owens C, Laurence V, Benboubker L, Defachelles AS, Cupissol D, Rubie H, Brisse H, Rey A, Ollivier L, Couanet D, Baunin C, Aït-Oukhatar CM, Oberlin O. Owens C, et al. Among authors: rey a. Cancer Chemother Pharmacol. 2013 Feb;71(2):399-404. doi: 10.1007/s00280-012-2015-7. Epub 2012 Nov 17. Cancer Chemother Pharmacol. 2013. PMID: 23161409 Clinical Trial.
1,248 results